Capmatinib and servotinib: Comparison of efficacy and safety in the treatment of non-small cell lung cancer

Capmatinib and servotinib, as targeted therapeutic drugs targeting epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) gene rearrangements, both play an important role in the treatment of non-small cell lung cancer (NSCLC). Although these two drugs have similar therapeutic targets, there are some differences in their clinical application, efficacy, and safety.

Capmatinib, as a highly selectiveMET inhibitor, is widely used to treat non-small cell lung cancer with MET gene amplification or MET exon 14 mutation. The results of multiple clinical studies show that capmatinib exhibits significant objective response rates for these specific types of NSCLC and brings durable anti-tumor effects to some patients. Its unique precision treatment strategy shows clear advantages, especially in patients who are resistant to traditional therapeutic drugs.

Compared with capmatinib, saivotinib is also a MET inhibitor and has excellent performance in the treatment of NSCLC patients whose disease has progressed after other regimens. Studies have shown that saivotinib has a good therapeutic effect on patients carrying MET gene mutations. In some clinical trials, its efficacy is comparable to capmatinib, and its side effects are milder. Some research reports indicate that saivotinib is better tolerated in specific patient groups and has a lower incidence of side effects, helping patients to better adhere to treatment.

When selecting these two drugs, in addition to considering their efficacy, it is also necessary to fully evaluate their potential side effects and the individual patient's condition. Possible side effects of capmatinib include abnormal liver function and gastrointestinal discomfort, while sevotinib may cause problems such as rash and elevated liver enzymes. In addition, the patient's quality of life is also a consideration that cannot be ignored, and some patients may prefer treatment options with fewer side effects.

Overall, despite similarities in efficacy, mechanism of action, and side effects between capmatinib and servotinib, subtle differences may still have an important impact on patient treatment options and prognosis. The two drugs may differ in terms of toxicity, but fundamentally they are relatively equivalent treatment options.